1832 Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

1832 Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-114,000	Closed	-$12.9M	–	763
2020 Q3	$12.9M	Hold	114,000	–	–	0.03%	240
2020 Q2	$12.8M	Sell	114,000 -224,609	-66%	-$23.8M	0.04%	223
2020 Q1	$29.8M	Buy	+338,609	New	+$33.2M	0.11%	143
2019 Q3	–	Sell	-898,200	Closed	-$112M	–	783
2019 Q2	$112M	Buy	898,200 +850,200	+1,771%	+$110M	0.36%	71
2019 Q1	$6.43M	Buy	+48,000	New	+$5.97M	0.02%	257
2017 Q4	–	Sell	-1,320	Closed	-$180K	–	755
2017 Q3	$180K	Buy	+1,320	New	+$179K	﹤0.01%	531
2016 Q1	–	Sell	-250,000	Closed	-$46.3M	–	713
2015 Q4	$46.3M	Buy	+250,000	New	+$43.7M	0.2%	118
2015 Q1	–	Sell	-666,000	Closed	-$122M	–	702
2014 Q4	$122M	Buy	666,000 +91,300	+16%	+$16.9M	0.38%	72
2014 Q3	$94.6M	Buy	574,700 +131,900	+30%	+$21.7M	0.31%	88
2014 Q2	$68.9M	Sell	442,800 -128,900	-23%	-$20.4M	0.22%	120
2014 Q1	$84.3M	Buy	571,700 +45,500	+9%	+$7.23M	0.29%	91
2013 Q4	$69.5M	Sell	526,200 -80,700	-13%	-$9.68M	0.27%	95
2013 Q3	$70M	Buy	+606,900	New	+$66.6M	0.31%	89

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

1832 Asset Management's ALXN Position: Q4 2020 in Review

1832 Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 114,000 shares — an estimated $12.9M sold.

1832 Asset Management first reported a position in ALXN in Q3 2013 and held it in 13 quarters. The position peaked at $122M in Q4 2014. 824 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

1832 Asset Management reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
1832 Asset Management sold 114,000 Alexion Pharmaceuticals shares in Q4 2020, an estimated $12.9M.
1832 Asset Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 13 quarters.
1832 Asset Management's Alexion Pharmaceuticals position peaked at $122M in Q4 2014.
824 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on 1832 Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.